PARADIGM BIOPHARMACEUTICALS LIMITED (PAR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PAR - PARADIGM BIOPHARMACEUTICALS LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index: ALL-ORDS

Paradigm Biopharmaceuticals is an Australian biotech company focused on the repurposing of the drug Pentosan Polysulphate Sodium for treatment of conditions sustained by inflammation. It has been listed since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.285

19 Apr
2024

0.000

OPEN

$0.29

0.000

HIGH

$0.30

481,103

LOW

$0.28

TARGET
$1.40 391.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PAR: 1
Title FY21
Actual
FY22
Actual
FY23
Forecast
FY24
Forecast
EPS (cps) xxx N/A - 17.9 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-17.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx18.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-45.2 M
Net Profit Margin xxxxxxxxxxxxxxx-111,013.71 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-108.16 %
Return on Invested Capital xxxxxxxxxxxxxxx-107.37 %
Return on Assets xxxxxxxxxxxxxxx-88.16 %
Return on Equity xxxxxxxxxxxxxxx-108.16 %
Return on Total Capital xxxxxxxxxxxxxxx-122.16 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx56 M
Price To Book Value xxxxxxxxxxxxxxx5.20

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx-
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx59 M
Research & Development xxxxxxxxxxxxxxx53 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

19/10/2023

1

Buy

$1.40

391.23%

In support of twelve month efficacy data released last week, Paradigm Biopharmaceuticals has released MRI data for it's PAR_OA_008 treatment, with Bell Potter noting combined, this strongly suggests the underlying cause of pain has been modified. 

The data demonstrated an increase in cartilage volume and thickness, reduction in bone marrow lesion volume, and reduction in inflammation. As far as Bell Potter is aware, no other treatment has demonstrated capability to not only halt disease progression, but also regenerate cartilage. 

Phase 3 dosing is expected to commence in the first quarter of 2024. The Buy rating and target price of $1.40 are retained.

FORECAST
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -17.90 cents.
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of 3.90 cents.

PAR STOCK CHART